Parkwalk Advisors

Parkwalk Advisors Research

Investment Thesis

Parkwalk Advisors (trading name of Parkwalk Advisors Ltd, FCA FRN 502237, registered at 3 Pancras Square, King's Cross, London) is the UK's most active investor in university spinouts and, by its own description, the largest growth EIS fund manager in the country. Founded in 2009 and part of IP Group plc since 2017, it backs deeptech companies built on defensible intellectual property that emerges from UK university research. The thesis is that world-class UK research stalls for lack of capital and that professionalised tech-transfer offices now give a clear path from lab to market. Parkwalk positions itself as the bridge between early academic discovery and later-stage venture capital.

Sectors

Parkwalk groups its focus into three core areas:

• DeepTech: AI, big data and software, digital media, hardware, materials, quantum computing
• HealthTech: digital health, life sciences, medtech
• CleanTech: agtech, future mobility, clean energy

The firm says it has backed over 200 spinouts, with more than 70 exits and over 200 million pounds returned to investors (data as at April 2026).

Stage Focus

The firm invests from Seed to Series C. The flagship Opportunities EIS Fund targets Series A to Series C companies. The university funds (Oxford, Cambridge, Imperial, Bristol, Northern Universities) target Seed to Series A, and the Northern Universities Venture Fund goes up to Series B. Companies must meet EIS rules: first commercial sale within seven years, fewer than 250 employees, gross assets under 15 million pounds.

Check Size

No firm-wide cheque size is published. Fund-level minimums apply to investors, for example 25,000 pounds in the Northern Universities Venture Fund. Individual deal sizes seen in public news are small to mid: Silvia Bio's 3 million pound seed, Cytotrait's 3 million pound seed, IVFmicro's 3.5 million pound pre-seed and Qkine's 1.5 million pound round, all syndicated, plus a 22.2 million pound Series C at Moa Technology.

Lead Tendency

In the Northern Universities Venture Fund's first three deals (Cytotrait, IVFmicro, Silvia Bio), Northern Gritstone led and the Parkwalk fund took part. Parkwalk directors take board seats at many portfolio companies. Overall lead tendency is not clearly established, so it is recorded as unknown.

Funds

• Opportunities EIS Fund and Knowledge Intensive EIS Funds: flagship funds investing in spinouts across sectors, Series A to C.
• Oxford Venture Fund: the seventh fund in the Oxford series, launched September 2026, managed with Oxford University Innovation, Seed to Series A.
• Northern Universities Venture Fund (NUVF): closed-end EIS fund run with Northern Gritstone, covering spinouts from Leeds, Liverpool, Manchester and Sheffield. It closed to subscriptions on 31 December 2025, with 5 to 10 portfolio companies and a 12 to 18 month deployment target.
• University of Cambridge Enterprise Funds, Imperial College Enterprise Funds and University of Bristol Enterprise Funds: partnership funds with each university's commercialisation arm.

Recent Activity

• October 2026: NUVF co-invested in Silvia Bio's 3 million pound seed (University of Sheffield), led by Northern Gritstone.
• September 2026: launched the Oxford Venture Fund; Qkine raised 1.5 million pounds.
• July 2026: portfolio company Moa Technology raised a 22.2 million pound Series C.
• April 2026: NUVF announced its first two investments, Cytotrait (Manchester) and IVFmicro (Leeds).
• September 2025: portfolio company Cytora was acquired by Applied Systems.
• Earlier exits include YASA (Mercedes-Benz, 2021) and PetMedix (Zoetis, 2023). The CIO also cites exits to Microsoft and Apple.

The fund is actively deploying.

Portfolio Highlights

The visible portfolio includes 1715 Labs, 52 North Health, 8Power, ACAL Energy, Accelercomm, Adsilico, Albus Health, Animal Dynamics, Aqdot, Arkivum, Arvia, Audiotelligence, Azul Optics, Barocal and BibliU. The team page and news also name Mind Foundry, Marley Health, Densix, Quantum Motion, Phasecraft, Symetrica, Echopoint, Cambridge GaN Devices, Crypto Quantique, Hynt, Moa Technology, Paragraf, PervasID, Evolito, Psyomics, Wayland Additive, Ikarovec, Gripable, K3 Metrology and M-Spin.

Team

• Moray Wright: Chief Executive Officer and co-founder; formerly Hoare Govett, JP Morgan, Lazard and Mirabaud; sits on the IP Group Executive Committee.
• John Pearson: Chief Investment Officer; formerly a partner at Adelphi Capital; led exits to Microsoft and Apple.
• Alun Williams: Investment Director; formerly Natwest Markets and Royal Bank of Canada.
• Anne Dobree: Investment Director; formerly led the University of Cambridge Seed Funds team.
• Martin Glen: Investment Director; former hedge fund manager and analyst.
• Neil Cameron: Investment Director responsible for quantum computing.
• Gordon Lawson: Non-Executive Chairman.
• Kathy Samii: Chief Operating Officer.
• Harriet Doherty and Susie Harris: sales, marketing and business development.
• Chloe Woodacre: Head of Investor Relations.
• Will Crompton: General Counsel.

Decision Process

Decisions run through an investment team of directors under the CIO, within IP Group's FCA-authorised structure. For the university funds, deal flow comes through the partner universities' tech-transfer offices and, for NUVF, Northern Gritstone.

Founder Preferences

Parkwalk backs academic founders and professors commercialising protected IP, often at the first institutional round. It works through university technology transfer offices and favours science-heavy teams.

Geographic Focus

UK only. Investments must be in UK companies that operate within the UK, with a strong emphasis on Oxford, Cambridge, Imperial, Bristol and the Northern Arc universities of Leeds, Liverpool, Manchester and Sheffield. Individual-investor funds are marketed to UK residents only.